A5038841996- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Multiple Myeloma Research and Treatments
- Pharmaceutical studies and practices
- Cancer therapeutics and mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Epigenetics and DNA Methylation
- Eosinophilic Disorders and Syndromes
- Blood disorders and treatments
- PI3K/AKT/mTOR signaling in cancer
- Biochemical and Molecular Research
- Cancer Treatment and Pharmacology
- Ubiquitin and proteasome pathways
Seattle Children's Hospital
2016-2025
Center for Cancer and Blood Disorders
2014-2025
University of Washington
2017-2025
Emory University
2009-2022
Children's Healthcare of Atlanta
2009-2022
Aflac (United States)
2013-2022
Seattle University
2021-2022
Fred Hutch Cancer Center
2018-2021
John Wiley & Sons (United States)
2020
Pediatrics and Genetics
2018
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and potential for efficacy of blinatumomab in children with relapsed/refractory precursor acute lymphoblastic leukemia (BCP-ALL). Methods This open-label study enrolled < 18 years old BCP-ALL phase I dosage-escalation part II part, using 6-week treatment cycles. Primary end points were maximum-tolerated dosage (phase I)...
Abstract BACKGROUND: The development of antigen‐targeted therapies may provide additional options to improve outcomes in children with acute myeloid leukemia (AML). Children's Oncology Group AAML03P1 trial sought determine the safety adding 2 doses gemtuzumab ozogamicin, a humanized anti‐CD33 antibody‐targeted agent, intensive chemotherapy during remission induction and postremission intensification for de novo AML. METHODS: enrolled 350 previously untreated Patients matched family donor...
The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine outcome R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013. Patient information, treatment, response were collected. Prognostic factors influencing complete remission (CR) rate event-free (EFS) analyzed. analytic set included...
NUP98 fusions comprise a family of rare recurrent alterations in AML, associated with adverse outcomes. In order to define the underlying biology and clinical implications this fusions, we performed comprehensive transcriptome, epigenome, immunophenotypic profiling 2,235 children young adults AML identified 160 rearrangements (7.2%), including 108 NUP98-NSD1 (4.8%), 32 NUP98-KDM5A (1.4%) 20 NUP98-X cases (0.9%) 13 different fusion partners. Fusion partners defined disease characteristics...
Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently adult acute myeloid leukemia (AML) and less commonly pediatric AML. The objective of this study was to describe the prevalence, mutational profile, prognostic significance IDH AML across age. Our cohort included 3141 patients aged between <1 month 88 years treated on Children's Cancer Group/Children's Oncology Group (n = 1872), Southwest 359), Eastern Cooperative 397) trials, Beat 333) Genome Atlas 180) genomic...
Abstract Background Plerixafor, a reversible CXCR4 antagonist, inhibits interactions between leukemic blasts and the bone marrow stromal microenvironment may enhance chemosensitivity. A phase 1 trial of plerixafor in combination with intensive chemotherapy children young adults relapsed or refractory acute lymphoblastic leukemia (ALL), myeloid (AML), myelodysplastic syndrome (MDS) was performed to determine tolerable biologically active dose. Procedure Plerixafor administered daily for 5...
To determine a safe and biologically active dose of quizartinib (AC220), potent selective class III receptor tyrosine kinase (RTK) FLT3 inhibitor, in combination with salvage chemotherapy children relapsed acute leukemia.Quizartinib was administered orally to AML or MLL-rearranged ALL following 5 days high-dose cytarabine etoposide (AE). A 3+3 escalation design used identify dose. Plasma inhibitory assay (PIA) testing performed weekly biologic activity.Toxicities were consistent intensive...
PURPOSE To determine whether dexrazoxane provides effective cardioprotection during frontline treatment of pediatric acute myeloid leukemia (AML) without increasing relapse risk or noncardiac toxicities the chemotherapy regimens. PATIENTS AND METHODS This was a multicenter study all patients with AML high allelic ratio FLT3/ITD treated in Children’s Oncology Group trial AAML1031 between 2011 and 2016. Median follow-up 3.5 years. Dexrazoxane administered at discretion treating physicians...
Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, liposomal preparation daunorubicin and cytarabine. sought to determine the recommended II dose (RP2D) CPX-351 response rate after up 2 cycles therapy.Children > 1 ≤ 21 years age relapsed/refractory AML were eligible finding; those in first relapse efficacy phase. Dose-limiting toxicity (DLT) assessment occurred during cycle 1. Two therapy offered (cycle 1:...
Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse independent cooperative group studies conducted by COG the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of last I-BFM trial until 2017, while 852 on Phase 3 trials (AAML0531, AAML1031). Overall at 5 years (OS) was 42 ± 4% (BFM) 35 2% (COG). Initial high-risk features (BFM 32...
Abstract Relapsed or refractory pediatric acute myeloid leukemia (AML) is associated with poor outcomes and relapse risk prediction approaches have not changed significantly in decades. To build a robust transcriptional model for AML, we perform RNA-sequencing on 1503 primary diagnostic samples. While 17 gene stem cell signature (LSC17) predictive our aggregated study population, LSC17 no longer within established cytogenetic molecular (cytomolecular) groups. Therefore, identify distinct LSC...
Background FLT3 /ITD is associated with poor outcomes in adult and pediatric acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation (HSCT) can improve cure rates, however relapse still common. Recent studies demonstrate the activity of inhibitors, including sorafenib, targeting underlying mutation. Procedure We conducted a retrospective study 15 patients /ITD+ AML treated sorafenib within 18 months after receiving HSCT. Sorafenib was administered either as...